TEL AVIV, Israel----VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced the upcoming presentation of preclinical data from the companys lead program, VB-201, at the European League Against Rheumatism Annual European Congress of Rheumatology.